TY - JOUR AU - Tang, J. AU - Shalabi, A. AU - Hubbard-Lucey, V. M. PY - 2018 DA - 2018// TI - Comprehensive analysis of the clinical immuno-oncology landscape JO - Ann Oncol VL - 29 UR - https://doi.org/10.1093/annonc/mdx755 DO - 10.1093/annonc/mdx755 ID - Tang2018 ER - TY - JOUR AU - Wei, S. C. AU - Duffy, C. R. AU - Allison, J. P. PY - 2018 DA - 2018// TI - Fundamental mechanisms of immune checkpoint blockade therapy JO - Cancer Discov VL - 8 UR - https://doi.org/10.1158/2159-8290.CD-18-0367 DO - 10.1158/2159-8290.CD-18-0367 ID - Wei2018 ER - TY - JOUR AU - Marin-Acevedo, J. A. AU - Dholaria, B. AU - Soyano, A. E. AU - Knutson, K. L. AU - Chumsri, S. AU - Lou, Y. PY - 2018 DA - 2018// TI - Next generation of immune checkpoint therapy in cancer: new developments and challenges JO - J Hematol Oncol VL - 11 UR - https://doi.org/10.1186/s13045-018-0582-8 DO - 10.1186/s13045-018-0582-8 ID - Marin-Acevedo2018 ER - TY - JOUR AU - Sledzinska, A. AU - Menger, L. AU - Bergerhoff, K. AU - Peggs, K. S. AU - Quezada, S. A. PY - 2015 DA - 2015// TI - Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy JO - Mol Oncol VL - 9 UR - https://doi.org/10.1016/j.molonc.2015.10.008 DO - 10.1016/j.molonc.2015.10.008 ID - Sledzinska2015 ER - TY - JOUR AU - Jago, C. B. AU - Yates, J. AU - Camara, N. O. AU - Lechler, R. I. AU - Lombardi, G. PY - 2004 DA - 2004// TI - Differential expression of CTLA-4 among T cell subsets JO - Clin Exp Immunol VL - 136 UR - https://doi.org/10.1111/j.1365-2249.2004.02478.x DO - 10.1111/j.1365-2249.2004.02478.x ID - Jago2004 ER - TY - JOUR AU - Arce Vargas, F. AU - Furness, A. J. S. AU - Litchfield, K. AU - Joshi, K. AU - Rosenthal, R. AU - Ghorani, E. PY - 2018 DA - 2018// TI - Fc effector function contributes to the activity of human anti-CTLA-4 antibodies JO - Cancer Cell VL - 33 UR - https://doi.org/10.1016/j.ccell.2018.02.010 DO - 10.1016/j.ccell.2018.02.010 ID - Arce Vargas2018 ER - TY - JOUR AU - Montler, R. AU - Bell, R. B. AU - Thalhofer, C. AU - Leidner, R. AU - Feng, Z. AU - Fox, B. A. PY - 2016 DA - 2016// TI - OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer JO - Clin Transl Immunology VL - 5 UR - https://doi.org/10.1038/cti.2016.16 DO - 10.1038/cti.2016.16 ID - Montler2016 ER - TY - JOUR AU - Du, X. AU - Tang, F. AU - Liu, M. AU - Su, J. AU - Zhang, Y. AU - Wu, W. PY - 2018 DA - 2018// TI - A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy JO - Cell Res VL - 28 UR - https://doi.org/10.1038/s41422-018-0011-0 DO - 10.1038/s41422-018-0011-0 ID - Du2018 ER - TY - JOUR AU - Gombos, R. B. AU - Gonzalez, A. AU - Manrique, M. AU - Chand, D. AU - Savitsky, D. AU - Morin, B. PY - 2018 DA - 2018// TI - Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody JO - PLoS One VL - 13 UR - https://doi.org/10.1371/journal.pone.0191926 DO - 10.1371/journal.pone.0191926 ID - Gombos2018 ER - TY - JOUR AU - Ingram, J. R. AU - Blomberg, O. S. AU - Rashidian, M. AU - Ali, L. AU - Garforth, S. AU - Fedorov, E. PY - 2018 DA - 2018// TI - Anti-CTLA-4 therapy requires an fc domain for efficacy JO - Proc Natl Acad Sci U S A VL - 115 UR - https://doi.org/10.1073/pnas.1801524115 DO - 10.1073/pnas.1801524115 ID - Ingram2018 ER - TY - JOUR AU - Romano, E. AU - Kusio-Kobialka, M. AU - Foukas, P. G. AU - Baumgaertner, P. AU - Meyer, C. AU - Ballabeni, P. PY - 2015 DA - 2015// TI - Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients JO - Proc Natl Acad Sci VL - 112 UR - https://doi.org/10.1073/pnas.1417320112 DO - 10.1073/pnas.1417320112 ID - Romano2015 ER - TY - JOUR AU - Sharma, A. n. u. AU - Subudhi, S. u. m. i. t. K. AU - Blando, J. o. r. g. e. AU - Scutti, J. o. r. g. e. AU - Vence, L. u. i. s. AU - Wargo, J. e. n. n. i. f. e. r. AU - Allison, J. a. m. e. s. P. AU - Ribas, A. n. t. o. n. i. AU - Sharma, P. a. d. m. a. n. e. e. PY - 2018 DA - 2018// TI - Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers JO - Clinical Cancer Research VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-18-0762 DO - 10.1158/1078-0432.CCR-18-0762 ID - Sharma2018 ER - TY - JOUR AU - Quezada, S. e. r. g. i. o. A. AU - Peggs, K. a. r. l. S. PY - 2018 DA - 2018// TI - Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4 JO - Clinical Cancer Research VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-18-2509 DO - 10.1158/1078-0432.CCR-18-2509 ID - Quezada2018 ER - TY - JOUR AU - Schadendorf, D. AU - Hodi, F. S. AU - Robert, C. AU - Weber, J. S. AU - Margolin, K. AU - Hamid, O. PY - 2015 DA - 2015// TI - Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in Unresectable or metastatic melanoma JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.56.2736 DO - 10.1200/JCO.2014.56.2736 ID - Schadendorf2015 ER - TY - JOUR AU - Eroglu, Z. AU - Kim, D. W. AU - Wang, X. AU - Camacho, L. H. AU - Chmielowski, B. AU - Seja, E. PY - 2015 DA - 2015// TI - Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab JO - Eur J Cancer VL - 51 UR - https://doi.org/10.1016/j.ejca.2015.08.012 DO - 10.1016/j.ejca.2015.08.012 ID - Eroglu2015 ER - TY - JOUR AU - Hodi, F. S. PY - 2010 DA - 2010// TI - Overcoming immunological tolerance to melanoma: Targeting CTLA-4 JO - Asia Pac J Clin Oncol VL - 6 UR - https://doi.org/10.1111/j.1743-7563.2010.01271.x DO - 10.1111/j.1743-7563.2010.01271.x ID - Hodi2010 ER - TY - JOUR AU - Bertrand, A. AU - Kostine, M. AU - Barnetche, T. AU - Truchetet, M. E. AU - Schaeverbeke, T. PY - 2015 DA - 2015// TI - Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis JO - BMC Med VL - 13 UR - https://doi.org/10.1186/s12916-015-0455-8 DO - 10.1186/s12916-015-0455-8 ID - Bertrand2015 ER - TY - JOUR AU - Ellmark, P. AU - Mangsbo, S. M. AU - Furebring, C. AU - Norlen, P. AU - Totterman, T. H. PY - 2017 DA - 2017// TI - Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation JO - Cancer Immunol Immunother VL - 66 UR - https://doi.org/10.1007/s00262-016-1909-3 DO - 10.1007/s00262-016-1909-3 ID - Ellmark2017 ER - TY - JOUR AU - Vetto, J. T. AU - Lum, S. AU - Morris, A. AU - Sicotte, M. AU - Davis, J. AU - Lemon, M. PY - 1997 DA - 1997// TI - Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers JO - Am J Surg VL - 174 UR - https://doi.org/10.1016/S0002-9610(97)00139-6 DO - 10.1016/S0002-9610(97)00139-6 ID - Vetto1997 ER - TY - STD TI - Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019. ID - ref20 ER - TY - JOUR AU - Redmond, W. L. AU - Linch, S. N. AU - Kasiewicz, M. J. PY - 2014 DA - 2014// TI - Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity JO - Cancer Immunol Res. VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-13-0031-T DO - 10.1158/2326-6066.CIR-13-0031-T ID - Redmond2014 ER - TY - JOUR AU - Emerson, D. A. AU - Redmond, W. L. PY - 2018 DA - 2018// TI - Overcoming tumor-induced immune suppression: from relieving inhibition to providing Costimulation with T cell agonists JO - BioDrugs. VL - 32 UR - https://doi.org/10.1007/s40259-018-0277-2 DO - 10.1007/s40259-018-0277-2 ID - Emerson2018 ER - TY - JOUR AU - Mayes, P. A. AU - Hance, K. W. AU - Hoos, A. PY - 2018 DA - 2018// TI - The promise and challenges of immune agonist antibody development in cancer JO - Nat Rev Drug Discov VL - 17 UR - https://doi.org/10.1038/nrd.2018.75 DO - 10.1038/nrd.2018.75 ID - Mayes2018 ER - TY - JOUR AU - Glisson, B. S. AU - Leidner, R. AU - Ferris, R. L. AU - Powderly, J. AU - Rizvi, N. AU - Norton, J. D. AU - Burton, J. AU - Lanasa, M. C. AU - Patel, S. P. PY - 2016 DA - 2016// TI - Phase 1 study of MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), in adult patients (pts) with advanced solid tumors JO - Ann Oncol VL - 27 ID - Glisson2016 ER - TY - JOUR AU - Jie, H. B. AU - Gildener-Leapman, N. AU - Li, J. AU - Srivastava, R. M. AU - Gibson, S. P. AU - Whiteside, T. L. PY - 2013 DA - 2013// TI - Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients JO - Br J Cancer VL - 109 UR - https://doi.org/10.1038/bjc.2013.645 DO - 10.1038/bjc.2013.645 ID - Jie2013 ER - TY - JOUR AU - Syed Khaja, A. S. AU - Toor, S. M. AU - Salhat, H. AU - Ali, B. R. AU - Elkord, E. PY - 2017 DA - 2017// TI - Intratumoral FoxP3(+)Helios(+) regulatory T cells upregulating immunosuppressive molecules are expanded in human colorectal Cancer JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.00619 DO - 10.3389/fimmu.2017.00619 ID - Syed Khaja2017 ER - TY - JOUR AU - Stewart, R. AU - Hammond, S. A. AU - Oberst, M. AU - Wilkinson, R. W. PY - 2014 DA - 2014// TI - The role of fc gamma receptors in the activity of immunomodulatory antibodies for cancer JO - Journal for ImmunoTherapy of Cancer VL - 2 UR - https://doi.org/10.1186/s40425-014-0029-x DO - 10.1186/s40425-014-0029-x ID - Stewart2014 ER - TY - STD TI - Waight JD, Gombos RB, Wilson NS. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: current approaches and future opportunities. Hum Antibodies. 2017. ID - ref28 ER - TY - JOUR AU - Waight, J. D. AU - Chand, D. AU - Dietrich, S. AU - Gombos, R. AU - Horn, T. AU - Gonzalez, A. M. PY - 2018 DA - 2018// TI - Selective FcgammaR co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens JO - Cancer Cell VL - 33 UR - https://doi.org/10.1016/j.ccell.2018.05.005 DO - 10.1016/j.ccell.2018.05.005 ID - Waight2018 ER - TY - STD TI - Stone E, O'Brien EM, Sanseviero E, Karras J, Shabaneh T, Aksoy BA, et al., Editors. Anti-CTLA4 activation of intratumoral NK cells may contribute to intratumoral Treg depletion. SITC'18, Washington DC; 9-11 November 2018. 6(suppl 1), Abstract O40. ID - ref30 ER - TY - JOUR AU - Sandin, L. C. AU - Eriksson, F. AU - Ellmark, P. AU - Loskog, A. S. AU - Totterman, T. H. AU - Mangsbo, S. M. PY - 2014 DA - 2014// TI - Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo JO - Oncoimmunology. VL - 3 UR - https://doi.org/10.4161/onci.27614 DO - 10.4161/onci.27614 ID - Sandin2014 ER - TY - JOUR AU - Selby, M. J. AU - Engelhardt, J. J. AU - Quigley, M. AU - Henning, K. A. AU - Chen, T. AU - Srinivasan, M. AU - Korman, A. J. PY - 2013 DA - 2013// TI - Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells JO - Cancer Immunology Research VL - 1 UR - https://doi.org/10.1158/2326-6066.CIR-13-0013 DO - 10.1158/2326-6066.CIR-13-0013 ID - Selby2013 ER - TY - JOUR AU - Simpson, T. R. AU - Li, F. AU - Montalvo-Ortiz, W. AU - Sepulveda, M. A. AU - Bergerhoff, K. AU - Arce, F. PY - 2013 DA - 2013// TI - Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma JO - J Exp Med VL - 210 UR - https://doi.org/10.1084/jem.20130579 DO - 10.1084/jem.20130579 ID - Simpson2013 ER - TY - JOUR AU - Mangsbo, S. M. AU - Sandin, L. C. AU - Anger, K. AU - Korman, A. J. AU - Loskog, A. AU - Totterman, T. H. PY - 2010 DA - 2010// TI - Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy JO - J Immunother VL - 33 UR - https://doi.org/10.1097/CJI.0b013e3181c01fcb DO - 10.1097/CJI.0b013e3181c01fcb ID - Mangsbo2010 ER - TY - JOUR AU - Quezada, S. A. AU - Peggs, K. S. AU - Curran, M. A. AU - Allison, J. P. PY - 2006 DA - 2006// TI - CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells JO - J Clin Invest VL - 116 UR - https://doi.org/10.1172/JCI27745 DO - 10.1172/JCI27745 ID - Quezada2006 ER - TY - JOUR AU - Hodi, F. S. AU - Butler, M. AU - Oble, D. A. AU - Seiden, M. V. AU - Haluska, F. G. AU - Kruse, A. PY - 2008 DA - 2008// TI - Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients JO - Proc Natl Acad Sci U S A VL - 105 UR - https://doi.org/10.1073/pnas.0712237105 DO - 10.1073/pnas.0712237105 ID - Hodi2008 ER - TY - JOUR AU - Sato, E. AU - Olson, S. H. AU - Ahn, J. AU - Bundy, B. AU - Nishikawa, H. AU - Qian, F. PY - 2005 DA - 2005// TI - Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer JO - Proc Natl Acad Sci U S A VL - 102 UR - https://doi.org/10.1073/pnas.0509182102 DO - 10.1073/pnas.0509182102 ID - Sato2005 ER - TY - JOUR AU - Liakou, C. I. AU - Kamat, A. AU - Tang, D. N. AU - Chen, H. AU - Sun, J. AU - Troncoso, P. PY - 2008 DA - 2008// TI - CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients JO - Proc Natl Acad Sci U S A VL - 105 UR - https://doi.org/10.1073/pnas.0806075105 DO - 10.1073/pnas.0806075105 ID - Liakou2008 ER - TY - STD TI - Ferrara R, Susini S, Marabelle A. Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers-letter. Clin Cancer Res. 2018. ID - ref39 ER - TY - JOUR AU - Sellers, R. S. AU - Clifford, C. B. AU - Treuting, P. M. AU - Brayton, C. PY - 2012 DA - 2012// TI - Immunological variation between inbred laboratory mouse strains: points to consider in phenotyping genetically immunomodified mice JO - Vet Pathol VL - 49 UR - https://doi.org/10.1177/0300985811429314 DO - 10.1177/0300985811429314 ID - Sellers2012 ER - TY - JOUR AU - Fiserova, A. AU - Richter, J. AU - Capkova, K. AU - Bieblova, J. AU - Mikyskova, R. AU - Reinis, M. PY - 2016 DA - 2016// TI - Resistance of novel mouse strains different in MHC class I and the NKC domain to the development of experimental tumors JO - Int J Oncol VL - 49 UR - https://doi.org/10.3892/ijo.2016.3561 DO - 10.3892/ijo.2016.3561 ID - Fiserova2016 ER - TY - JOUR AU - Elsas, A. AU - Hurwitz, A. A. AU - Allison, J. P. PY - 1999 DA - 1999// TI - Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation JO - J Exp Med VL - 190 UR - https://doi.org/10.1084/jem.190.3.355 DO - 10.1084/jem.190.3.355 ID - Elsas1999 ER - TY - JOUR AU - Xu, D. AU - Gu, P. AU - Pan, P. Y. AU - Li, Q. AU - Sato, A. I. AU - Chen, S. H. PY - 2004 DA - 2004// TI - NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation JO - Int J Cancer VL - 109 UR - https://doi.org/10.1002/ijc.11696 DO - 10.1002/ijc.11696 ID - Xu2004 ER - TY - JOUR AU - Selby, M. J. AU - Engelhardt, J. J. AU - Johnston, R. J. AU - Lu, L. S. AU - Han, M. AU - Thudium, K. PY - 2016 DA - 2016// TI - Preclinical development of Ipilimumab and Nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and Cynomolgus macaque toxicology JO - PLoS One VL - 11 UR - https://doi.org/10.1371/journal.pone.0161779 DO - 10.1371/journal.pone.0161779 ID - Selby2016 ER - TY - STD TI - Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017. ID - ref45 ER - TY - JOUR AU - Tawbi, H. A. AU - Forsyth, P. A. AU - Algazi, A. AU - Hamid, O. AU - Hodi, F. S. AU - Moschos, S. J. PY - 2018 DA - 2018// TI - Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1805453 DO - 10.1056/NEJMoa1805453 ID - Tawbi2018 ER - TY - JOUR AU - Postow, M. A. AU - Chesney, J. AU - Pavlick, A. C. AU - Robert, C. AU - Grossmann, K. AU - McDermott, D. PY - 2015 DA - 2015// TI - Nivolumab and ipilimumab versus ipilimumab in untreated melanoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1414428 DO - 10.1056/NEJMoa1414428 ID - Postow2015 ER -